Acute Care Therapeutics for Surgical Settings

Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings.

About Baudax Bio

We currently have multiple therapeutic candidates across early, mid and late-stage clinical development, including a FDA approved non-opioid therapy for use in the acute care setting.

About Us
Our Innovative Pipeline

Our Innovative Pipeline

Our product pipeline contains valuable therapeutic product candidate options for patients and healthcare providers in acute care settings.

ANJESO (meloxicam) injection Product Pipeline

Latest News

Baudax Bio Announces Full Commercial Launch of ANJESO™ and Receipt of Unique C-Code and Pass-Through Payment Status Effective July 1, 2020

View Press Release

Baudax Bio Announces Full Commercial Launch of ANJESO™ and Receipt of Unique C-Code and Pass-Through Payment Status Effective July 1, 2020

View Press Release

Baudax Bio Secures $50 Million Credit Facility

View Press Release

Baudax Bio Reports First Quarter 2020 Financial Results

View Press Release

Baudax Bio Announces Presentation of New Phase IIIb ANJESO™ Data at Digestive Disease Week 2020

View Press Release

Baudax Bio Announces Change in Location of its 2020 Annual Meeting of Shareholders to its Corporate Headquarters

View Press Release

Baudax Bio Announces Presentation of New Phase IIIb ANJESO™ Data at the 45th Annual Regional Anesthesiology and Acute Pain Medicine Meeting

View Press Release

Baudax Bio Announces U.S. Availability of ANJESO™ (meloxicam) Injection for the Management of Moderate to Severe Pain

View Press Release

Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View Press Release

Baudax Bio Announces Closing of $25 Million Public Offering of Securities

View Press Release

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today